Susan Seibert

Susan Seibert

Auto-generated profile, based on publicly available information

Susan Seibert

Center for Neurology, University of Bonn Medical Center, Bonn, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Zeitschrift für Neuropsychologie
Verified
Journal Article
Open access
SSSusan Seibert
Susan Seibert
AHAlexander Hanke
Alexander Hanke
MWMichelle Wieberneit
Michelle Wieberneit
LBLuzie Bieler
Luzie Bieler
RGRobin Gräfenkämper
Robin Gräfenkämper
CWCatherine Nichols Widmann
Catherine Nichols Widmann
This review assesses neurocognitive studies on long-/post-COVID-19 adult patients, highlighting the research gaps. We categorize populations by infection severity, demographics, inclusion of controls, and psychological/biological factors. Methodologically, we analyzed 73 studies (95,600 subjects) from December 2019 to October 2022 using PRISMA-ScR guidelines and the PICO framework. Our findings revealed that most studies lacked control groups (88 %) and reported unclear overall cognitive outcomes (73 %). While the studies frequently assessed executive functions (86 %) and attention (85 %), there were few longitudinal studies. Varied reporting on sample sizes further complicated the analysis. The identified gaps encompass convenience sampling, limited longitudinal studies, and inadequate use of cognitive test batteries, leading to a discrepancy between expected and reported outcomes. The absence of standardized comparisons and inconsistent statistical methods exacerbated these gaps.

18 September 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSusan Seibert
Susan Seibert
IEIrina Eckert
Irina Eckert
CWCatherine Nichols Widmann
Catherine Nichols Widmann
TETaraneh Ebrahimi
Taraneh Ebrahimi
FBFabian Boesl
Fabian Boesl
OSOmid Shirvani
Omid Shirvani
Binary (0 = male, 1 = female). Rhombus (red) indicates significant result (p < 0.05), while circles (orange) represent nonsignificant results.

7 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSusan Seibert
Susan Seibert
IEIrina Eckert
Irina Eckert
CWCatherine Nichols Widmann
Catherine Nichols Widmann
TETaraneh Ebrahimi
Taraneh Ebrahimi
FBFabian Boesl
Fabian Boesl
OSOmid Shirvani
Omid Shirvani
Neurological post-COVID condition (PCC) often involves attentional deficits that impact daily functioning. Traditional paper-based tests, like the Trail-Making Test (TMT), may inadequately capture these impairments due to their short duration and dependence on numerical and alphabetic sequencing. This study evaluates the validity of three subtests of the computerized Test for Attentional Performance (TAP) as alternatives for detecting attentional impairments in PCC. In the ongoing NEURO LC-19 DE study, 108 subjects aged 18 to 79 years, with PCC-related cognitive complaints (n = 67, 73% f) and healthy controls (n = 41, 56% f) underwent neuropsychological testing. The prevalence of impairment and classification ability of the TAP subtests were evaluated alongside standard paper-based tests, including the TMT and Montreal Cognitive Assessment, using receiver operating characteristic (ROC) analysis and regression. The TAP subtests identified significant impairments in sustained attention and processing speed in one-third of PCC patients, surpassing traditional tests in sensitivity, and classifying PCC with an AUC of 78%. Omissions in sustained attention significantly differentiated groups (OR = 1.14, p = 0.016, 95% CI [1.02–1.26]). Fatigue correlated with poorer performance on speed and accuracy (r > 0.30, p < 0.05). Cognitive slowing is prevalent in neurological PCC but is scarcely captured by conventional assessments. The TAP’s computerized format with automated norming and independence from alphanumeric stimuli shows promise in improving the discriminatory ability for identifying attentional deficits in PCC patients.

4 November 2026 in BMC Psychology
Verified
Journal Article
Open access
PDF file
VKVanessa Kauffmann
Vanessa Kauffmann
SSSusan Seibert
Susan Seibert
MHMichael Thomas Heneka
Michael Thomas Heneka
JRJascha Rüsseler
Jascha Rüsseler
CWCatherine Nichols Widmann
Catherine Nichols Widmann
Background: This study aimed to investigate the longitudinal change of verbal fluency after COVID-19 and potential influencing factors in a community-based sample. Within the COVIMMUNE-Clin study at the University of Bonn Medical Center, participants with a mild course of COVID-19 ( n = 52), a severe course ( n = 52), and healthy controls ( n = 55) were compared. This focused secondary analysis examined verbal fluency as a distinct cognitive outcome within the broader study. Methods: Semantic and lexical verbal fluency, assessed using the Vienna Verbal Fluency Test (WIWO), as well as psychological burden measured by the ICD-10 Symptom Rating Scale (ISR) and subjective complaints assessed with the Everyday Cognition-12 (ECog-12) questionnaire, were administered at the first visit and again after 12 months. A linear mixed model was employed, incorporating Group (mild, severe and healthy controls) and Visit as fixed effects, with Subject and the Intercept as random effects. ISR and ECog-12 were each incorporated into separate models as fixed effects. Results: Group and psychological burden had an impact on semantic fluency, in a way that more severe disease and higher psychological burden were associated with lower performance. Contrary to the hypothesis, verbal fluency did not significantly change over 12 months. Across models, verbal fluency types showed distinctive patterns, which is reflected by the fact that psychological burden and subjective complaints only showed an association with semantic fluency performance. Lexical fluency showed no significant effects of these constructs and was primarily positively influenced by education. Conclusion: COVID-19 disease severity, psychological burden, and subjective complaints were associated with semantic fluency. These findings support further research on whether verbal fluency measures, in combination with self-reported symptoms, may contribute to practical assessment approaches following COVID-19. Trial registration: Specific details of the study design are included at the German Clinical Trials Registry (primary registry trial identifier: DRKS00023806; registration date: March 16, 2021, cross-referenced at World Health Organization’s International Clinical Trials Registry Platform [ICTRP]).